Insights about U.S. Stocks that landed in the Green-Zone during Thursday’s trade, are depicted underneath:
Aoxing Pharmaceutical Company, Inc (NYSEMKT:AXN)’s stock skyrocketed 40.35%, and closed at $1.12.
Formerly on February 17, Aoxing Pharmaceutical Corporation, Inc. (AXN), a specialty pharmaceutical corporation focusing on research, development, manufacturing, and distribution of narcotic, pain-administration, and addiction treatment pharmaceuticals, declared its financial and operational results for the quarter ended December 31, 2014.
Second Quarter 2015 Highlights:
- Proceeds in the second quarter raised 85% year over year to $6.4 million while cost of sales reduced 20% year over year to $1.6 million. Gross profit for the second quarter was $4.8 million, representing a 75% gross margin, and an raise of 233% as contrast to the same quarter last year.
- Net profit for the second quarter was $0.6 million instead of a net loss of $1.9 million for the same quarter last year.
- Net cash generated from operating activities for the six months ended December 31, 2014 was $3.4 million contrast to the use of $2.8 million cash in operations for the period ended December 31, 2013.
- Basic and diluted revenue per ordinary share were both $0.01 for the second quarter as contrast to net loss of ($0.04) per basic and diluted share for the same quarter last year.
Aoxing Pharmaceutical Corporation, Inc. is a US incorporated specialty pharmaceutical corporation with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-administration products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China State Food and Drug Administration (SFDA).
Geron Corporation (NASDAQ:GERN), picked up 34.52%, and closed at $3.78.
Geron Corporation (GERN), stated financial results for the fourth quarter and year ended December 31, 2014 and recent events.
Fourth Quarter 2014 Results:
Net loss for the fourth quarter of 2014 was $8.9 million, or $0.06 per share, contrast to $9.3 million, or $0.07 per share, for the comparable 2013 period. Proceeds for the fourth quarter of 2014 were $178,000 contrast to $225,000 for the comparable 2013 period. The corporation ended 2014 with $170.6 million in cash and investments, which comprised of receipt of an upfront payment of $35.0 million for the license rights granted by the corporation to Janssen Biotech, Inc. (“Janssen”) under the exclusive partnership and license contract (the “Partnership Contract”) reached between the parties in November 2014, which has been recorded as deferred proceed as of December 31, 2014.
Total operating expenses for the fourth quarter of 2014 were $9.2 million contrast to $9.5 million for the comparable 2013 period. Research and development expenses for the fourth quarter of 2014 were $4.4 million contrast to $5.1 million for the comparable 2013 period. General and administrative expenses for the fourth quarter of 2014 were $4.8 million contrast to $4.0 million for the comparable 2013 period. Operating expenses for the 2013 fourth quarter also comprised of restructuring charges of $430,000 in connection with the corporation`s decisions to discontinue its discovery research programs and close its research laboratory facility in 2013.
Year-End 2014 Results;
Net loss for 2014 was $35.7 million, or $0.23 per share, contrast to $38.4 million, or $0.30 per share, for 2013. License fee and royalty proceeds for 2014 and 2013 were $1.2 million and $1.3 million, respectively.
Total operating expenses for 2014 were $37.5 million contrast to $40.2 million for 2013. Research and development expenses for 2014 were $20.7 million contrast to $23.2 million for 2013. General and administrative expenses for 2014 were $16.8 million contrast to $15.6 million for 2013. Year-to-date operating expenses for 2013 also comprised of restructuring charges of $1.5 million.
The decrease in research and development expenses for 2014 contrast to 2013 primarily reflects the net result of lower clinical trial expenses with the wind-down of the imetelstat trials in solid tumors and GRN1005 trials in patients with brain metastases and reduced personnel-related and other research costs resulting from previous restructurings and the discontinuation of the corporation`s discovery research programs, partially offset by higher costs for the manufacturing of imetelstat drug product. The raise in general and administrative expenses for 2014 contrast to 2013 primarily reflects the net result of higher non-cash stock-based compensation expense, raised legal fees for the purported lawsuits filed against the corporation and transaction costs associated with the Partnership Contract with Janssen, partially offset by reduced patent fees and transaction costs associated with the closing of the stem cell divestiture transaction.
Interest and other revenue was $373,000 for 2014 contrast to $951,000 for 2013. The decrease in interest and other revenue for 2014 contrast to 2013 primarily reflects the net result of a gain on the sale of excess laboratory equipment in 2013, partially offset by higher interest revenue due to raised cash and investment balances in 2014.
Geron Corporation, a clinical stage biopharmaceutical corporation, develops a telomerase inhibitor, imetelstat, to treat hematologic myeloid malignancies. The corporation was founded in 1990 and is based in Menlo Park, California.
Vivint Solar Inc (NYSE:VSLR), enhanced 33.06%, and closed at $11.35.
Vivint Solar, Inc. (VSLR), declared financial results for the fourth quarter and year ended December 31, 2014.
Fourth Quarter 2014 Operating Highlights:
Key operating and development highlights for the quarter ended December 31, 2014 comprise:
- MW Booked of about 52 MWs for the quarter, up about 150% year-over-year.
- MW Installed of about 50 MWs, up 191% year-over-year. Total cumulative MWs installed were about 228 MWs as of December 31, 2014.
- Installations were 6,864 for the quarter, up 135% year-over-year. Cumulative installations were 35,720 as of December 31, 2014.
- Estimated Nominal Contracted Payments Remaining raised by about $188 million during the quarter and was about $1,031 million at December 31, 2014, up 161% year-over-year.
- Estimated Retained Value raised by about $82 million during the quarter to about $481 million at December 31, 2014, up 153% contrast to the fourth quarter of 2013.
- Estimated Retained Value per Watt was $2.11 as of December 31, 2014.
Vivint Solar is a leading provider of distributed solar energy systems – electricity generated by a solar energy system installed at a customer’s location – to residential customers in the United States. Vivint Solar’s customers pay little to no money upfront, receive noteworthysavings relative to utility generated electricity rates and continue to benefit from guaranteed energy prices over the 20-year term of their contracts.
CorMedix Inc.(NYSEMKT:CRMD), gained 25.97%, and closed at $7.76, hitting new 52-week high of $7.83.
CorMedix, Inc. (CRMD), a pharmaceutical corporation focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases, declared several planned business updates.
CorMedix Engages Evercore as Financial Advisor to Explore Planned Alternatives:
CorMedix declared recently that it has retained investment bank Evercore as financial advisor to explore planned alternatives, in order to accelerate the global development of Neutrolin® Catheter Lock Solution and maximize shareholder value.
“Based on our ongoing belief in the value and clinical potential of Neutrolin® as an important product to address a noteworthy medical need, the CorMedix Board and administration has retained Evercore to evaluate and identify planned alternatives aimed to accelerate the product’s global development and commercialization,” said Randy Milby, CorMedix Chief Executive Officer. “We believe Evercore’s premier reputation, track record, and industry expertise will assist us to maximize the value of Neutrolin® more efficiently.”
Neutrolin® is a novel formulation of taurolidine, citrate and heparin 1000 u/ml that provides a combination preventative solution, decreases the triple threat of infection, thrombosis and biofilm to keep catheters operating safely and efficiently by optimizing catheter blood flow while minimizing infections and biofilm formation for oncology, hemodialysis, and intensive care patients. Neutrolin® has CE mark approval for use in the European Union and was recently approved to enter a Phase 3 program in the United States. The U.S. Food and Drug Administration (FDA) has designated Neutrolin®, as a Qualified Infectious Disease Product (QIDP), which provides an additional five years of market exclusivity in addition to the five years granted for a New Chemical Entity under Hatch-Waxman patent exclusivity.
CorMedix Inc. is a commercial-stage pharmaceutical corporation that seeks to in-license, develop and commercialize therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases.
